---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-077088"
form_type: "8-K"
ticker: null
cik: "0001827087"
company_name: "Vigil Neuroscience, Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T08:00:38.600813+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vigil Neuroscience Q4 2023 net loss $22.2M; positive Phase 2 interim data for iluzanebart; cash runway extended

## Summary
- Q4 2023 net loss from operations $22.2M (vs $18.5M Q4 2022); full year net loss $82.6M (vs $68.3M 2022).
- Cash, cash equivalents, and marketable securities $117.9M at Dec 31, 2023; cash runway extended into H2 2025.
- Phase 2 IGNITE trial for iluzanebart in ALSP: positive interim data showing target engagement; enrollment completed with 20 patients; next data readout Q3 2024.
- VG-3927 Phase 1 trial ongoing; interim data planned mid-2024; FDA partial clinical hold on maximum exposure limit, no expected delay.
- Appointed Petra Kaufmann, M.D., as Chief Medical Officer.

## SEC filing metadata
- accession: 0001193125-24-077088
- form_type: 8-K
- cik: 0001827087
- company_name: Vigil Neuroscience, Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1827087/000119312524077088/0001193125-24-077088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1827087/000119312524077088/d796361d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-077088
- JSON: https://secwatch.observer/filing/0001193125-24-077088.json
- Plain text: https://secwatch.observer/filing/0001193125-24-077088.txt

## Key facts
- Earnings Releases
  Vigil Neuroscience, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: Vigil Neuroscience, Inc . (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1827087/000119312524077088/0001193125-24-077088-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.